322 related articles for article (PubMed ID: 24324582)
1. High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time.
He YF; Zhang MY; Wu X; Sun XJ; Xu T; He QZ; Di W
PLoS One; 2013; 8(12):e79769. PubMed ID: 24324582
[TBL] [Abstract][Full Text] [Related]
2. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.
Zhang M; He Y; Sun X; Li Q; Wang W; Zhao A; Di W
J Ovarian Res; 2014 Feb; 7():19. PubMed ID: 24507759
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma].
Wan T; Liu JH; Zheng LM; Cai MY; Ding T
Ai Zheng; 2009 Mar; 28(3):323-7. PubMed ID: 19619451
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
Yuan X; Zhang J; Li D; Mao Y; Mo F; Du W; Ma X
Gynecol Oncol; 2017 Oct; 147(1):181-187. PubMed ID: 28698008
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry.
Rakaee M; Busund LR; Jamaly S; Paulsen EE; Richardsen E; Andersen S; Al-Saad S; Bremnes RM; Donnem T; Kilvaer TK
Neoplasia; 2019 Mar; 21(3):282-293. PubMed ID: 30743162
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells.
Li H; Yang B; Huang J; Lin Y; Xiang T; Wan J; Li H; Chouaib S; Ren G
Oncotarget; 2015 Oct; 6(30):29637-50. PubMed ID: 26359357
[TBL] [Abstract][Full Text] [Related]
7. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse.
Reinartz S; Schumann T; Finkernagel F; Wortmann A; Jansen JM; Meissner W; Krause M; Schwörer AM; Wagner U; Müller-Brüsselbach S; Müller R
Int J Cancer; 2014 Jan; 134(1):32-42. PubMed ID: 23784932
[TBL] [Abstract][Full Text] [Related]
8. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
[TBL] [Abstract][Full Text] [Related]
9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer.
Whynott RM; Manahan P; Geisler JP
Eur J Gynaecol Oncol; 2016; 37(2):164-6. PubMed ID: 27172738
[TBL] [Abstract][Full Text] [Related]
12. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors.
Beeghly-Fadiel A; Wilson AJ; Keene S; El Ramahi M; Xu S; Marnett LJ; Fadare O; Crispens MA; Khabele D
J Ovarian Res; 2018 Feb; 11(1):17. PubMed ID: 29482584
[TBL] [Abstract][Full Text] [Related]
13. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A
BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472
[TBL] [Abstract][Full Text] [Related]
14. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
Lesnock JL; Darcy KM; Tian C; Deloia JA; Thrall MM; Zahn C; Armstrong DK; Birrer MJ; Krivak TC
Br J Cancer; 2013 Apr; 108(6):1231-7. PubMed ID: 23462720
[TBL] [Abstract][Full Text] [Related]
16. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
17. Differential mucin phenotypes and their significance in a variation of colorectal carcinoma.
Imai Y; Yamagishi H; Fukuda K; Ono Y; Inoue T; Ueda Y
World J Gastroenterol; 2013 Jul; 19(25):3957-68. PubMed ID: 23840140
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
19. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary.
Hanski C; Hofmeier M; Schmitt-Gräff A; Riede E; Hanski ML; Borchard F; Sieber E; Niedobitek F; Foss HD; Stein H; Riecken EO
J Pathol; 1997 Aug; 182(4):385-91. PubMed ID: 9306958
[TBL] [Abstract][Full Text] [Related]
20. Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer--A Potential Relationship.
Jernigan AM; Mahdi H; Rose PG
Int J Gynecol Cancer; 2015 Sep; 25(7):1232-8. PubMed ID: 26067864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]